January 18, 2017 10:03 PM ET


Company Overview of Biovest International Inc.

Company Overview

Biovest International, Inc., a biotechnology company, develops therapeutic cancer vaccines in the United States. It operates in two segments, Instrumentation and Vaccine. The company develops and commercializes BiovaxID, a personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. It is also involved in the development, manufacture, and sale of instruments and disposables, including AutovaxID, an automated cell culture system that enables production of personalized cell-based treatments; HF Primer, a cell culture system for producing small quantities of the cell culture products from mammalian cell lines; and Multi-6, a cell culture system for producing small scale qu...

300 South Hyde Park Avenue

Suite 210

Tampa, FL 33606

United States

Founded in 1981

41 Employees





Key Executives for Biovest International Inc.

Chief Executive Officer and President
Age: 39
Executive Chairman and Member of Compensation Committee
Age: 69
Chief Medical Officer
Director of Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2016.

Biovest International Inc. Key Developments

Aytu Bioscience, Inc. Enters into a Master Services Agreement with Biovest International, Inc

On October 8, 2015, Aytu Bioscience Inc. entered into a Master Services Agreement with Biovest International Inc., pursuant to which Biovest is to provide manufacturing services to Aytu. The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at Aytu's expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, Aytu may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Biovest International Inc., please visit www.biovest.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.